<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T12:05:54Z</responseDate>
  <request identifier="oai:figshare.com:article/34040133" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34040133</identifier>
        <datestamp>2026-10-01T05:48:52Z</datestamp>
        <setSpec>category_15</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Data Sheet 2_Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch.pdf</dc:title>
          <dc:creator>Carlye Frisch (25152909)</dc:creator>
          <dc:creator>Lauren Baker (5448857)</dc:creator>
          <dc:creator>Gayathri Srinivasan (308717)</dc:creator>
          <dc:creator>Albert E. Mintah (25152912)</dc:creator>
          <dc:creator>Salma Leyasi (25152915)</dc:creator>
          <dc:creator>Morgan Pedroza (25152918)</dc:creator>
          <dc:creator>Brooke Galyon (25152921)</dc:creator>
          <dc:creator>David A. Brafman (3349484)</dc:creator>
          <dc:subject>Neuroscience</dc:subject>
          <dc:subject>Alzheimer’s disease</dc:subject>
          <dc:subject>amyloid precursor protein processing</dc:subject>
          <dc:subject>APOE3 Christchurch</dc:subject>
          <dc:subject>APP duplication</dc:subject>
          <dc:subject>induced pluripotent stem cells</dc:subject>
          <dc:subject>isogenic models</dc:subject>
          <dc:subject>PSEN1 E280A</dc:subject>
          <dc:subject>tau phosphorylation</dc:subject>
          <dc:description>Introduction&lt;p&gt;Alzheimer’s disease (AD) is a progressive neurodegenerative disorder influenced by both causal mutations and genetic modifiers. The rare APOE3 Christchurch (APOE3ch) variant has been associated with delayed disease onset in a familial Alzheimer’s disease case, suggesting a potential protective role. However, the mechanisms underlying this protection, particularly across different genetic backgrounds, remain unclear.&lt;/p&gt;Methods&lt;p&gt;We generated isogenic human induced pluripotent stem cell (hiPSC)–derived neural cultures harboring either PSEN1 E280A or amyloid precursor protein duplication (APPdp) mutations, with and without the APOE3ch variant, using prime editing. Neural differentiation, amyloid-beta production, amyloid precursor protein processing, tau phosphorylation and transcriptomic profiles were assessed.&lt;/p&gt;Results&lt;p&gt;APOE3ch did not affect neural differentiation or apolipoprotein E secretion. However, it exhibited mutation-dependent effects on Alzheimer’s disease phenotypes. In amyloid precursor protein duplication cultures, APOE3ch significantly reduced amyloid-beta production and shifted processing toward non-amyloidogenic pathways, accompanied by decreased phosphorylated tau. In contrast, in PSEN1 E280A cultures, APOE3ch had minimal impact on amyloid-beta levels but increased non-amyloidogenic processing and altered total tau without affecting phosphorylation. Transcriptomic analysis revealed both shared and mutation-specific effects, with consistent modulation of pathways related to synaptic function, including Wnt and cadherin signaling.&lt;/p&gt;Discussion&lt;p&gt;These findings demonstrate that APOE3ch acts as a context-dependent modifier of Alzheimer’s disease pathology, with protective effects varying by genetic background. The variant consistently influences pathways associated with synaptic resilience while differentially modulating amyloid and tau pathology. This work provides mechanistic insight into APOE3ch-mediated protection and highlights the importance of genetic context in developing targeted therapeutic strategies for Alzheimer’s disease.&lt;/p&gt;</dc:description>
          <dc:date>2026-10-01T05:48:52Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fnagi.2026.1856154.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Data_Sheet_2_Isogenic_human_stem_cell_models_reveal_mutation-dependent_protective_mechanisms_of_APOE3_Christchurch_pdf/34040133</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
